Quest Diagnostics EBITDA Margin 2010-2025 | DGX
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Quest Diagnostics (DGX) over the last 10 years. The current EBITDA margin for Quest Diagnostics as of March 31, 2025 is .
| Quest Diagnostics EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2025-03-31 |
$10.16B |
$1.91B |
18.79% |
| 2024-12-31 |
$9.87B |
$1.84B |
18.63% |
| 2024-09-30 |
$9.54B |
$1.72B |
18.02% |
| 2024-06-30 |
$9.35B |
$1.72B |
18.37% |
| 2024-03-31 |
$9.29B |
$1.71B |
18.36% |
| 2023-12-31 |
$9.25B |
$1.70B |
18.39% |
| 2023-09-30 |
$9.30B |
$1.58B |
16.95% |
| 2023-06-30 |
$9.49B |
$1.62B |
17.11% |
| 2023-03-31 |
$9.60B |
$1.66B |
17.27% |
| 2022-12-31 |
$9.88B |
$1.87B |
18.87% |
| 2022-09-30 |
$10.29B |
$2.26B |
21.92% |
| 2022-06-30 |
$10.58B |
$2.51B |
23.71% |
| 2022-03-31 |
$10.68B |
$2.65B |
24.79% |
| 2021-12-31 |
$10.79B |
$2.79B |
25.85% |
| 2021-09-30 |
$11.05B |
$3.04B |
27.52% |
| 2021-06-30 |
$11.06B |
$3.09B |
27.98% |
| 2021-03-31 |
$10.34B |
$2.83B |
27.41% |
| 2020-12-31 |
$9.44B |
$2.33B |
24.71% |
| 2020-09-30 |
$8.36B |
$1.88B |
22.53% |
| 2020-06-30 |
$7.53B |
$1.47B |
19.55% |
| 2020-03-31 |
$7.66B |
$1.49B |
19.43% |
| 2019-12-31 |
$7.73B |
$1.56B |
20.19% |
| 2019-09-30 |
$7.64B |
$1.42B |
18.54% |
| 2019-06-30 |
$7.57B |
$1.40B |
18.52% |
| 2019-03-31 |
$7.54B |
$1.40B |
18.52% |
| 2018-12-31 |
$7.53B |
$1.41B |
18.72% |
| 2018-09-30 |
$7.56B |
$1.45B |
19.20% |
| 2018-06-30 |
$7.52B |
$1.44B |
19.10% |
| 2018-03-31 |
$7.47B |
$1.44B |
19.28% |
| 2017-12-31 |
$7.40B |
$1.44B |
19.39% |
| 2017-09-30 |
$7.10B |
$1.43B |
20.18% |
| 2017-06-30 |
$7.13B |
$1.45B |
20.35% |
| 2017-03-31 |
$7.17B |
$1.55B |
21.60% |
| 2016-12-31 |
$7.21B |
$1.53B |
21.15% |
| 2016-09-30 |
$7.50B |
$1.50B |
19.99% |
| 2016-06-30 |
$7.50B |
$1.82B |
24.31% |
| 2016-03-31 |
$7.52B |
$1.72B |
22.83% |
| 2015-12-31 |
$7.49B |
$1.70B |
22.73% |
| 2015-09-30 |
$7.53B |
$1.73B |
22.93% |
| 2015-06-30 |
$7.55B |
$1.35B |
17.92% |
| 2015-03-31 |
$7.53B |
$1.32B |
17.53% |
| 2014-12-31 |
$7.44B |
$1.30B |
17.44% |
| 2014-09-30 |
$7.31B |
$1.30B |
17.83% |
| 2014-06-30 |
$7.19B |
$1.73B |
24.00% |
| 2014-03-31 |
$7.11B |
$1.74B |
24.55% |
| 2013-12-31 |
$7.15B |
$1.76B |
24.60% |
| 2013-09-30 |
$7.16B |
$1.75B |
24.47% |
| 2013-06-30 |
$7.20B |
$1.37B |
19.05% |
| 2013-03-31 |
$7.26B |
$1.42B |
19.49% |
| 2012-12-31 |
$7.38B |
$1.49B |
20.15% |
| 2012-09-30 |
$7.37B |
$1.54B |
20.90% |
| 2012-06-30 |
$7.45B |
$1.56B |
20.91% |
| 2012-03-31 |
$7.48B |
$1.54B |
20.64% |
| 2011-12-31 |
$7.39B |
$1.27B |
17.15% |
| 2011-09-30 |
$7.35B |
$1.23B |
16.68% |
| 2011-06-30 |
$7.31B |
$1.23B |
16.85% |
| 2011-03-31 |
$7.28B |
$1.27B |
17.45% |
| 2010-12-31 |
$7.26B |
$1.54B |
21.18% |
| 2010-09-30 |
$7.39B |
$1.59B |
21.44% |
| 2010-06-30 |
$7.43B |
$1.60B |
21.49% |
| 2010-03-31 |
$7.45B |
$1.59B |
21.36% |
| 2009-12-31 |
$7.46B |
$1.62B |
21.68% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$19.755B |
$9.872B |
|
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
|
